• Return to Headlines

Relatively High Future Earnings Growth Detected in Shares of Vanda Pharmaceut in the Biotechnology Industry (VNDA, BMRN, AMAG, GHDX, PDLI)

By Shiri Gupta

Below are the three companies in the Biotechnology industry with the highest future earnings growth. The growth of earnings per share (next fiscal year estimated vs. current fiscal year estimated) is important to gauge future profitability and relative value. Higher EPS growth generally justifies higher earnings multiples.

Vanda Pharmaceut ranks highest with a future earnings growth of 221.5%. Following is Biomarin Pharmac with a future earnings growth of 191.3%. Amag Pharmaceuti ranks third highest with a future earnings growth of 116.3%.

Genomic Health I follows with a future earnings growth of 111.4%, and Pdl Biopharma In rounds out the top five with a future earnings growth of 84.9%.

SmarTrend recommended that subscribers consider buying shares of Pdl Biopharma In on October 15th, 2019 as our technology indicated a new Uptrend was in progress when shares hit $2.42. Since that recommendation, shares of Pdl Biopharma In have risen 40.5%. We continue to monitor Pdl Biopharma In for any potential shift so investors can protect gains and will alert SmarTrend subscribers immediately.

Keywords: highest future earnings growth vanda pharmaceut biomarin pharmac amag pharmaceuti genomic health i pdl biopharma in

Ticker(s): VNDA BMRN AMAG GHDX PDLI